Replies to post #183377 on Biotech Values

[DewDiligence]

FDA approves Daiichi Sankyo’s Savaysa (edoxaban) for multiple indications:

http://in.reuters.com/article/2015/01/09/us-daiichi-fda-idINKBN0KI00120150109

Savaysa, like Xarelto and Eliquis (but not Pradaxa) is Factor Xa inhibitor. I don’t think it has any differentiating characteristics relative to the other FXa drugs, so I doubt it will garner a substantial market share.

In Japan, edoxaban is approved under the brand name, Lixiana (#msg-62357482).